Laurion Capital Management’s Aktis Oncology AKTS Stock Holding History

Laurion Capital Management’s Portfolio AKTS Stock Details AKTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.79M	Buy	+100,000	New	+$1.94M	0.08%	222

Other funds holding AKTS

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Laurion Capital Management's AKTS Position: Q1 2026 in Review

Laurion Capital Management opened a new position in Aktis Oncology (AKTS) in Q1 2026: 100,000 shares worth $1.79M. The stake represents 0.08% of the portfolio and ranks #222 among its holdings.

69 funds tracked by Wall St. Rank hold AKTS as of Q1 2026.

Laurion Capital Management held 100,000 shares of Aktis Oncology worth $1.79M as of Q1 2026.
Aktis Oncology was a new Laurion Capital Management position in Q1 2026.
Aktis Oncology made up 0.08% of Laurion Capital Management's portfolio in Q1 2026, its #222 holding.
69 funds tracked by Wall St. Rank held Aktis Oncology as of Q1 2026.

Based on Laurion Capital Management's 13F filing for Q1 2026, filed 14 May 2026.